Quantity not sufficient rates and delays in sweat testing in US infants with cystic fibrosis.


Journal

Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590

Informations de publication

Date de publication:
11 2020
Historique:
received: 03 06 2020
revised: 06 08 2020
accepted: 07 08 2020
pubmed: 17 8 2020
medline: 18 3 2021
entrez: 16 8 2020
Statut: ppublish

Résumé

Diagnostic sweat testing is required for infants with positive newborn-screening (NBS) tests for cystic fibrosis (CF). Infants have "quantity not sufficient" (QNS) sweat volumes more often than older children. A comprehensive study of QNS sweat volumes in infants has not previously been reported. We surveyed US CF Centers to obtain QNS rates in all infants who had sweat testing at under 14 days and under 3 months of age. We then calculated QNS rates reported to the Cystic Fibrosis Foundation Patient Registry (CFFPR) 2010-2018 in 10-day increments from 1 to 60 days of life. We compared QNS sweat test rates in preterm (<37-weeks gestational age) vs term infants. We assessed age at sweat test and proportion of infants who did not have a sweat test reported by 60 days of age. Thirty-nine of 144 (27%) of CF Centers reported a mean QNS rate of 10.5% (range, 0-100) in infants 14-days-old or younger. CFFPR data showed the highest QNS rates in the youngest infants and in those born before 37 weeks of gestation. The median age at sweat testing decreased over time, but more than 22% of infants did not have a sweat test reported by 60 days. Higher QNS rates are seen in the youngest infants with CF, but more than 80% of infants younger than 2 weeks of age have adequate sweat volumes. Sweat testing should not be delayed in infants with a positive CF NBS test.

Sections du résumé

BACKGROUND
Diagnostic sweat testing is required for infants with positive newborn-screening (NBS) tests for cystic fibrosis (CF). Infants have "quantity not sufficient" (QNS) sweat volumes more often than older children. A comprehensive study of QNS sweat volumes in infants has not previously been reported.
METHODS
We surveyed US CF Centers to obtain QNS rates in all infants who had sweat testing at under 14 days and under 3 months of age. We then calculated QNS rates reported to the Cystic Fibrosis Foundation Patient Registry (CFFPR) 2010-2018 in 10-day increments from 1 to 60 days of life. We compared QNS sweat test rates in preterm (<37-weeks gestational age) vs term infants. We assessed age at sweat test and proportion of infants who did not have a sweat test reported by 60 days of age.
RESULTS
Thirty-nine of 144 (27%) of CF Centers reported a mean QNS rate of 10.5% (range, 0-100) in infants 14-days-old or younger. CFFPR data showed the highest QNS rates in the youngest infants and in those born before 37 weeks of gestation. The median age at sweat testing decreased over time, but more than 22% of infants did not have a sweat test reported by 60 days.
CONCLUSION
Higher QNS rates are seen in the youngest infants with CF, but more than 80% of infants younger than 2 weeks of age have adequate sweat volumes. Sweat testing should not be delayed in infants with a positive CF NBS test.

Identifiants

pubmed: 32797669
doi: 10.1002/ppul.25027
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3053-3056

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

LeGrys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzel PJ, Cystic Fibrosis Foundation. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr. 2007;151(1):85-89.
CLSI. Sweat testing: specimen collection and quantitative chloride analysis. CLSI Guideline C34. 4th ed.Wayne, PA: Clinical and Laboratory Standards Institute; 2019.
Kleyn M, Korzeniewski S, Grigorescu V, et al. Predictors of insufficient sweat production during confirmatory testing for cystic fibrosis. Pediatr Pulmonol. 2011;46(1):23-30.
Eng W, LeGrys VA, Schechter MS, Laughon MM, Barker PM. Sweat-testing in preterm and full-term infants less than 6 weeks of age. Pediatr Pulmonol. 2005;40(1):64-67.
Collins MN, Brawley CB, McCracken CE, Shankar PR, Schechter MS, Rogers BB. Risk factors for quantity not sufficient sweat collection in infants 3 months or younger. Am J Clin Pathol. 2014;142(1):72-75.
Legrys VA, McColley SA, Li Z, Farrell PM. The need for quality improvement in sweat testing infants after newborn screening for cystic fibrosis. J Pediatr. 2010;157(6):1035-1037.
Cirilli N, Padoan R, Raia V, ICFS Sweat Test Working Group, et al. Audit of sweat testing: a first report from Italian Cystic Fibrosis Centres. J Cyst Fibros. 2008;7:415-422.
Knapp EA, Fink AK, Goss CH, et al. The Cystic Fibrosis Foundation Patient Registry. Design and methods of a National Observational Disease Registry. Ann Am Thorac Soc. 2016;13:1173-1179.
Tluczek A, Koscik RL, Farrell PM, Rock MJ. Psychosocial risk associated with newborn screening for cystic fibrosis: parents' experience while awaiting the sweat-test appointment. Pediatrics. 2005;115(6):1692-1703.
Farrell PM, White TB, Howenstine MS, et al. Diagnosis of cystic fibrosis in screened populations. J Pediatr. 2017;181S:S33-S44.
Farrell PM, White TB, Ren CL, et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017;181S:S4-S15.
Laguna TA, Lin N, Wang Q, Holme B, McNamara J, Regelmann WE. Comparison of quantitative sweat chloride methods after positive newborn screen for cystic fibrosis. Pediatr Pulmonol. 2012;47(8):736-742.
Bergougnoux A, Boureau-Wirth A, Rouzier C, et al. A false positive newborn screening result due to a complex allele carrying two frequent CF-causing variants. J Cyst Fibros. 2016;15(3):309-312.

Auteurs

Susanna A McColley (SA)

Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.

Alexander Elbert (A)

Cystic Fibrosis Foundation, Bethesda, Maryland.

Runyu Wu (R)

Cystic Fibrosis Foundation, Bethesda, Maryland.

Clement L Ren (CL)

Department of Pediatrics, Riley Children's Hospital, Indiana University, Indianapolis, Indiana.

Marci K Sontag (MK)

Center for Public Health Innovation, Littleton, Colorado.
Department of Epidemiology, University of Colorado, Denver.

Vicky A LeGrys (VA)

Department of Allied Health Science, University of North Carolina, Chapel Hill, North Carolina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH